Tag Archives: cardiovascular disease

December, 2016

5 December
FDA Approves Jardiance to Reduce CV Risk in Patients with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 5, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is the first type 2 diabetes treatment approved with …
Share

31 October
FDA Approves New Device for Prevention of Recurrent Strokes in Certain Patients

ST. PAUL, Minn.–(BUSINESS WIRE)–St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the AMPLATZER™ PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO) – a …
Share
19 October
The Medicines Company’s PCSK9 Drug Demonstrates Positive Results in Mid-Stage Study

PARSIPPANY, N.J.–(BUSINESS WIRE)–The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor. Data from the interim analysis confirm the significant and durable LDL-C reduction demonstrated up …
Share

12 October
Lilly Discontinues Development of its Experimental Cholesterol Drug

INDIANAPOLIS, Oct. 12, 2015 /PRNewswire/ — Eli Lilly and Company and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy. Lilly will discontinue development of evacetrapib for the treatment of …
Share

28 August
FDA Approves Amgen’s PCSK9 Inhibitor Repatha

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to …
Share